Alnylam Pharmaceuticals, Inc. balance sheet

At the end of fiscal 2025, Alnylam Pharmaceuticals, Inc. had total assets of $4.97bn, total liabilities of $4.18bn and shareholders' equity of $789m. It held $1.66bn in cash against $1.01bn of debt: net cash of $649m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Alnylam Pharmaceuticals, Inc.: balance sheet, annual
Fiscal year	2008Dec 2008	2009Dec 2009	2010Dec 2010	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Cash and equivalents	192	137	75	194	645	420	547	497	820	866	813	966	1,657
Receivables	—	6	3	23	34	19	43	102	199	238	328	405	778
Inventory	—	—	—	—	—	24	56	75	86	129	89	79	83
Total current assets	—	294	254	672	1,765	1,201	1,716	2,615	2,809	2,692	2,983	3,295	4,051
Total assets	—	481	393	1,263	1,995	1,575	2,395	3,407	3,643	3,546	3,830	4,240	4,966
Accounts payable	—	12	9	54	28	60	50	52	73	98	56	88	116
Deferred revenue (current)	—	82	81	34	7	3	78	127	149	42	103	55	5
Total current liabilities	—	111	102	132	144	179	353	585	696	768	968	1,186	1,466
Long-term debt	—	—	—	—	—	—	—	191	676	—	—	—	—
Total debt	0	0	0	150	30	30	0	191	676	1,017	1,021	1,025	1,008
Total liabilities	—	303	235	343	228	273	956	2,391	3,055	3,705	4,051	4,173	4,177
Shareholders' equity	202	178	158	920	1,766	1,302	1,439	1,016	588	−158	−221	67	789
Net debt (negative = net cash)	−192	−137	−75	−44	−615	−390	−547	−305	−144	151	208	58	−649
Shares outstanding	—	42m	85m	86m	100m	101m	112m	116m	120m	124m	126m	129m	132m

US$ millions unless shown otherwise. Fiscal quarters.

Alnylam Pharmaceuticals, Inc.: balance sheet, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q2Jun 2026	2026 Q3Sept 2026
Receivables	354	405	418	567	965	778	913	1,085
Inventory	76	79	66	72	75	83	97	106
Total current assets	3,355	3,295	3,268	3,644	3,953	4,051	4,620	5,113
Total assets	4,205	4,240	4,214	4,566	4,852	4,966	5,559	7,995
Accounts payable	71	88	97	102	118	116	108	135
Deferred revenue (current)	71	55	28	15	3	5	4	12
Total current liabilities	1,221	1,186	1,076	1,301	1,555	1,466	1,513	2,063
Total liabilities	4,173	4,173	4,098	4,315	4,618	4,177	4,205	4,391
Shareholders' equity	32	67	426	555	580	789	1,354	3,604
Non-controlling interests and other (assets − liabilities − equity)	—	—	−311	−305	−346	—	—	—
Shares outstanding	129m	129m	130m	131m	132m	132m	134m	134m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: ALNY vs NBIX ALNY vs BMRN ALNY vs ARGX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Alnylam Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Alnylam Pharmaceuticals, Inc.